RxDoctor Payments Data

John Miskovsky, MD

Internal Medicine · Pawtucket, RINPI 1497743330

Payments from drug & device makers

$2,245in general payments, 2019–2025

Across 38 payments — averaging $59.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$250
  • Eisai Inc.$245
  • Takeda Pharmaceuticals U.S.A., Inc.$232
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$221
  • Stryker$171
  • Exact Sciences$166
  • plus $959 from 14 others

What the payments were for

  • Food & beverage$2,245100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,245 in reported general payments places this provider in the 85th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$84,167
Medicare patients
260
Services billed
705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin104$93,770
OzempicSemaglutide57$57,691
XifaxanRifaximin13$48,424
MounjaroTirzepatide47$46,894
EliquisApixaban49$35,874
JanuviaSitagliptin Phosphate43$35,350
Breo ElliptaFluticasone/Vilanterol46$24,434
Repatha SureclickEvolocumab25$17,295
TradjentaLinagliptin15$11,186
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,754
Spiriva HandihalerTiotropium Bromide16$9,965
Sumatriptan Succinate13$7,915
LivaloPitavastatin Calcium16$6,901
DuleraMometasone/Formoterol11$4,957
Atorvastatin Calcium355$3,532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$90$104,955119 claims
Novo NordiskOzempic$41$57,69157 claims
Lilly USA, LLCMounjaro$26$46,89447 claims
PfizerEliquis$19$35,87449 claims
AbbVieSynthroid$130$1,41915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Pawtucket

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →